Publications. Coya shall have the sole right to publish, present or otherwise disclose the results of its Development of the Licensed Compound and Products; provided that at least 60 days prior to making any such publication, presentation or disclosure, Coya shall provide ARScience Bio with a copy of such publication, presentation or disclosure (and the intended date of such publication, presentation or disclosure) and Coya shall # review and consider in good faith any comments provided by ARScience Bio and # redact any Confidential Information of ARScience Bio upon ARScience Bio’s request.

Publications. Each Party recognizes that the publication of papers regarding results of and other information regarding activities under this Agreement may be beneficial to the potential of the research undertaken pursuant to this Agreement. All publications, and other forms of public disclosure such as abstracts and presentations, of results of studies carried out under this Agreement (each of the foregoing, a “Publication”) will comply with the strategy established by the JSC and will not contain the Confidential Information of the other Party without the other Party’s advance written consent. Neither Party nor their Affiliates may submit for publication, publish or present a Publication without the opportunity for prior review by the other Party, except to the extent required by applicable Laws. A Party seeking, or whose Affiliate is seeking, to submit, publish, or present a Publication shall provide the other Party the opportunity to review and comment on the proposed Publication at least ​ (​) Business Days prior to its intended submission for publication or presentation. The other Party shall provide the Party seeking, or whose Affiliate is seeking, to publish or present with its comments in writing, if any, within ​ days after receipt of such proposed Publication. The Party seeking, or whose Affiliate is seeking, to publish, or present shall consider in good faith any comments thereto provided by the other Party and shall comply with the other Party’s request to remove any and all of such other Party’s Confidential Information from the proposed Publication. In addition, the Party seeking, or whose Affiliate is seeking, to publish, or present shall delay the submission for a period of up to an additional ​ days in the event that the other Party can demonstrate reasonable need for such delay in order to prepare and file a patent application for which it has prosecution control pursuant to this Agreement. If the other Party fails to provide its comments to the Party seeking, or whose Affiliate is seeking, to publish or present within such ​ (​)-day period, such other Party shall be deemed not to have any comments, and the Party seeking, or whose Affiliate is seeking, to publish or present shall be free to submit for publication or present in accordance with this [Section 10.5] after the ​ (​)-Business Day period has elapsed. The Party seeking, or whose Affiliate is seeking, to publish or present shall provide the other Party a copy of the manuscript, abstract or presentation at the time of the submission or presentation, as applicable. Each Party agrees to acknowledge the contributions of the other Party and its Affiliates and their employees in all publications, as scientifically appropriate.

Publications. Upon completion of a Clinical Trial and evaluation by NVCR of all data from such study, or upon early termination or abandonment of such study, upon prior written approval by NVCR, Zai may publicly present or publish any Clinical Trial data, non-clinical data or any associated results or conclusions generated by or on behalf of Zai pursuant to this Agreement solely for non-commercial purposes and solely to the extent that such data, results and conclusions are specific to the Territory and the Field (each such proposed presentation or publication, a “Publication”), provided that Zai may only make such Publication in accordance with NVCR’s global publication strategy with respect to Licensed Products, and subject to the additional limitations set forth in this [Section 10.4].

Publications. Consultant agrees to submit to Aligos any proposed publication that contains any discussion relating to Aligos, Proprietary Information, Aligos Work Product and any Proprietary Rights therein, or Services performed hereunder. Consultant further agrees that no such publication shall be made without the prior written consent of Aligos.

Publications. In furtherance of the rights reserved in Section 2.3(c) of this Agreement, UABRF or its Affiliates shall submit the proposed publication or disclosure to the Licensee at least ​ prior to submission for publication or disclosure to allow the Licensee to review the matter for disclosure of Proprietary Information of the Licensee. The Licensee shall have ​ from its receipt of such proposed publication or disclosure to review and to provide written notice to UABRF or its Affiliate who provided the submission requiring removal of the Licensee's Proprietary Information and UABRF or its Affiliate shall remove the Licensee's Proprietary Information prior to publication or disclosure. If the Licensee does not provide written notice of such request to UABRF or its Affiliate who provided the submission within ​ after receipt of the proposed publication or disclosure from UABRF or its Affiliate, UABRF or its Affiliate shall be free to publish or disclose to third parties the proposed publication or disclosure without further obligation to the Licensee.

Publications. Upon completion of a Clinical Trial and evaluation by NVCR of all data from such study, or upon early termination or abandonment of such study, upon prior

During the Term, on a ​, each Party shall provide the JSC its proposed publication schedule for the subsequent ​. Prior to public disclosure or submission for publication of a proposed publication describing the results of any scientific or clinical activity relating to a Licensed Antibody or Product, # Ono, and # upon Ono’s reasonably request in good faith, [[Forty Seven:Organization]] (in each case, the “Submitting Party”) shall send the other Party (the “Responding Party”) a copy of the proposed publication to be submitted and shall allow the Responding Party a reasonable time period (but no less than ​) for the Responding Party # to determine whether the proposed publication contains subject matter for which patent protection should be sought (prior to publication of such proposed publication) for the purpose of protecting an invention, # to determine whether the proposed publication contains the Confidential Information of the Responding Party, or # to provide the Submitting Party with its reasonable comments to such proposed publication, which the Submitting Party shall consider in good faith. Following the expiration of the applicable time period for review, the Submitting Party shall be free to submit such proposed publication for publication or otherwise disclose to the public such scientific or clinical results, subject to the procedures set forth in [Section 11.3.2]. For clarity, a Party shall not be obligated to delay disclosure or submission of such publication pursuant to the foregoing timelines with respect to publications that do not contain any patentable subject matter or any of the other Party’s Confidential Information.

Publications. During the Term, each Party will submit to the other Party (the “Non-Disclosing Party”) for review and approval any proposed academic, scientific and medical publication or public presentation which contains the Non-Disclosing Party’s Confidential Information. In addition, each Party will submit to the other Party for its review and approval any proposed publication or public presentation relating to the Research Program. In both instances, such review and approval will be conducted for the purposes of preserving the value of the Licensed Intellectual Property, [[Cellectis:Organization]] CAR-T Developed IP and Allogene CAR-T Developed IP and the rights granted to each Party hereunder and determining whether any portion of the proposed publication or presentation containing the Non-Disclosing Party’s Confidential Information should be modified or deleted. Written copies of such proposed publication or presentation required to be submitted hereunder will be submitted to the Non-Disclosing Party no later than thirty (30) days before submission for publication or presentation (the “Review Period”). The Non-Disclosing Party will provide its comments with respect to such publications and presentations within twenty (20) days after its receipt of such written copy, and the other Party will delete any Confidential Information of the Non-Disclosing Party upon request. The Review Period may be extended for an additional sixty (60) days in the event the Non-Disclosing Party can, within fifteen (15) days of receipt of the written copy, demonstrate reasonable need for such extension, including for the preparation and filing of patent applications. [[Cellectis:Organization]] and Allogene will each comply with standard academic practice regarding authorship of scientific publications and recognition of contribution of other parties in any publication governed by this [Section 7.3.2].

Publications. Subject to [Section 9.3], Reata and its Affiliates shall be free to publish, and Reata may authorize its Sublicensees to publish, the results of any preclinical study or clinical trial of a Targeted AIM or Targeted AIM Product conducted by or on behalf of Reata or its Affiliate or Sublicensees. [[AbbVie:Organization]] shall have the right to publish one publication regarding the results of Development conducted under the License Agreement and Collaboration Agreement prior to the A&R Date, subject to Reata’s prior approval (not to be unreasonably withheld, conditioned or delayed); provided that [[AbbVie:Organization]] shall deliver a then-current copy of such publication to Reata at least twenty (20) days prior to submitting such publication to a publisher (provided that the Parties may agree to a shorter period), and Reata shall review such publication and give its comments and approval decision to [[AbbVie:Organization]] within ten (10) days of the delivery of such publication to Reata; provided, further, that failure to respond within such ten (10)-day period shall be deemed approval to publish. Except as provided in the immediately preceding sentence, [[AbbVie:Organization]] shall not, and shall cause its Affiliates not, to publish any non-public information with respect to a Compound or Royalty Product.

During the Agreement Term, the following restrictions shall apply with respect to disclosure by any Party of Confidential Information relating to the Product in any publication or presentation: